前列腺癌HDR近距离治疗单次19Gy与两次13.5Gy随机II期疗效对比
这项随机II期试验纳入170例低危或中危前列腺癌患者,比较单次19Gy与两次13.5Gy HDR单药治疗的疗效。中位随访60个月,两次方案5年生化无病生存率95%、局部失败率3%,均显著优于单次方案的73.5%和29%;单次方案不应使用。
要点
- 两次13.5Gy方案5年生化无病生存率95%,局部失败率3%。
- 单次19Gy方案5年生化无病生存率73.5%,局部失败率29%,疗效较差。
- 两方案泌尿毒性无差异,2级泌尿毒性45%,3级1%。
核心结论
- HDR单药治疗采用两次13.5Gy方案耐受性好且5年肿瘤控制率高。
- 单次19Gy单药治疗方案疗效较差,不应使用。
研究设计与样本
- 随机II期临床试验,纳入170例低危或中危前列腺癌患者。
- 患者随机接受单次19Gy或间隔一周两次13.5Gy的HDR单药治疗。
- 中位年龄65岁,中位PSA 6.33 ng/ml,Grade Group 1、2、3分别占28%、60%、12%。
主要发现
- 中位随访60个月,两次方案PSA下降更快(p=0.009)。
- 5年时中位PSA单次方案为0.65 ng/ml,两次方案为0.16 ng/ml。
- 5年生化无病生存率单次方案73.5%,两次方案95%(p=0.001)。
- 5年局部失败累积发生率单次方案29%,两次方案3%(p<0.001)。
- 复发与初始分期、分级分组或风险分组无关。
关键数值与推荐
- 生化失败采用Phoenix定义,局部失败均经活检确认。
- 毒性采用CTCAE v.4评估,2级晚期直肠毒性发生率1%。
- 2级和3级泌尿毒性发生率分别为45%和1%,两组间无差异。
临床怎么用
- 低危或中危前列腺癌患者可选择两次13.5Gy HDR单药治疗方案。
- 不应采用单次19Gy HDR单药治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: High dose-rate (HDR) brachytherapy as monotherapy is a treatment option for localized prostate cancer, but optimal dose and fractionation is unknown. We report efficacy results of a randomized phase II trial of HDR monotherapy delivered as either one or two fractions. MATERIALS AND METHODS: Eligible patients had low or intermediate risk prostate cancer, prostate volume <60 cc, and no androgen deprivation use. 170 patients were randomized to receive HDR as either a single fraction of 19 Gy or as two fractions of 13.5 Gy one week apart. Median age was 65 years, median PSA was 6.33 ng/ml, and Grade Group 1, 2 and 3 was present in 28%, 60%, and 12%, respectively. There was no difference in baseline factors between arms and 19%, 51% and 30% had low risk, favourable intermediate and unfavourable intermediate risk disease, respectively. The Phoenix definition was used to define biochemical failure, all local failures were confirmed by biopsy and toxicity was assessed using CTCAE v.4. RESULTS: Median follow-up was 60 months. PSA decreased more quickly in the 2-fraction arm (p = 0.009). Median PSA at 5-years was 0.65 ng/ml in the single fraction and 0.16 ng/ml in the 2-fraction arm. The 5-year biochemical disease-free survival and cumulative incidence of local failure was 73.5% and 29% in the single fraction arm and 95% (p = 0.001) and 3% (p < 0.001) in the 2-fraction arm, respectively. Recurrence was not associated with initial stage, grade group, or risk group. Grade 2 late rectal toxicity occurred in 1% while the incidence of grade 2 and 3 urinary toxicity was 45% and 1%, respectively, with no difference between arms. CONCLUSIONS: HDR monotherapy delivered as two fraction of 13.5 Gy is well tolerated with a high cancer control rate at 5 years. Single fraction monotherapy is inferior and should not be used.
引用
- Morton G, McGuffin M, Chung HT, et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol. 2020. PMID: 32146259. doi:10.1016/j.radonc.2020.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。